With a history of exceeding expectations, Cardiol Therapeutics Inc Class A is about to report its earnings soon. Investors are closely watching to see if it can keep this trend going.
Cardiol Therapeutics Inc Class A (CRDL.TO) will release its next earnings report on August 13, 2026, after the market closes. The pharmaceutical company is in the spotlight as it prepares to share its financial results for the fiscal period ending June 30, 2026. With a consensus EPS estimate of -$0.10, market participants are eager to find out if Cardiol can maintain its recent track record of beating earnings expectations.
Recent earnings trend
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeAdvertisement
Market cap
$237.46M
52W high
$2.33
52W low
$1.23
1W change
+9.90%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 184.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+184.4% Upside
Current Price
C$2.11
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
60.9%
Annualized
90-Day Vol
56.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.24 | C$1.82 – C$2.76 |
| 60 trading days | C$2.38 | C$1.77 – C$3.20 |
| 90 trading days | C$2.52 | C$1.75 – C$3.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 3 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | — | -0.1000 | — |
| 2026-03-31 | 2026-05-12 | -0.0719 | -0.0900 | +20.1% |
| 2025-12-31 | 2026-03-31 | -0.0700 | -0.1100 | +36.4% |
| 2025-09-30 | 2025-11-13 | -0.1200 | -0.1000 | -20.0% |
| 2025-06-30 | 2025-08-14 | -0.1000 | -0.1200 | +16.7% |
| 2025-03-31 | 2025-05-14 | -0.1000 | -0.1300 | +23.1% |
Advertisement
Investor takeaway: Keep an eye on the company’s recent performance history. Cardiol has surpassed earnings estimates in three out of its last four quarters. The upcoming report will be crucial in determining whether this trend continues, especially given the current EPS estimate and the company’s recent advancements in clinical trials.
EPS Estimate: -$0.10, Historical Beat Rate: 75%
Cardiol has beaten earnings estimates in three of the last four quarters, showing a strong ability to exceed expectations despite a generally negative EPS outlook.
Bull case
The bull case for Cardiol is based on its solid history of earnings surprises and recent positive developments in clinical research. Notably, the results from its Phase II study were published in a reputable journal. This could boost investor confidence and potentially lead to higher stock prices.
Bear case
On the other hand, the company still faces challenges with a negative EPS and no revenue expected for the upcoming quarter. If the earnings report falls short of even the lowered expectations, it could lead to a sharp decline in investor sentiment.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
